semaglutide
Tirzepatide vs Semaglutide: Mortality Advantage Revealed
Answer: Tirzepatide shows lower mortality than semaglutide in obesity treatment, with a 22% lower hazard ratio for all-cause death in real-world cohorts. In head-to-head trials, the dual GLP-1/GIP agonist also delivered modest improvements in cardiovascular outcomes, while semaglutide’s data remain limited to early post-marketing surveillance. Medical Disclaimer: This